DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

BIBLIOGRAPHY
Anderson GL, Limacher M, Assaf AR, et al. for The Women’s
Health Initiative Steering Committee. Effects of conjugated
equine estrogen in postmenopausal women with hysterectomy:
The Women’s Health Initiative randomized controlled trial.
JAMA, 2004, 291:1701–1712.
Aronica SM, Katzenellenbogen BS. Stimulation of estrogen
receptor-mediated transcription and alteration in the phosphorylation
state of the rat uterine estrogen receptor by estrogen,
cyclic adenosine monophosphate, and insulin-like growth
factor-I. Mol Endocrinol, 1993, 7:743–752.
Belchetz PE. Hormonal treatment of postmenopausal women.
N Engl J Med, 1994, 330:1062–1071.
Beral V, for the Million Women Study Collaborators. Breast cancer
and hormone-replacement therapy in the Million Women
Study. Lancet, 2003, 362:419–427.
Blackmore PF. Extragenomic actions of progesterone in human
sperm and progesterone metabolites in human platelets.
Steroids, 1999, 64:149–156.
Braidman I, Baris C, Wood L, et al. Preliminary evidence for
impaired estrogen receptor-α protein expression in osteoblasts
and osteocytes from men with idiopathic osteoporosis. Bone,
2000, 26:423–427.
Burkman R, Schlesselman JJ, Zieman M. Safety concerns and
health benefits associated with oral contraception. Am J Obstet
Gynecol, 2004, 190(suppl 4):S5–S22.
Castelli WP. Cardiovascular disease: Pathogenesis, epidemiology,
and risk among users of oral contraceptives who smoke.
Am J Obstet Gynecol, 1999, 180:349S–356S.
Cheskis BJ, Karathanasis S, Lyttle CR. Estrogen receptor ligands
modulate its interaction with DNA. J Biol Chem, 1997,
272:11384–11391.
Christin-Maitre S, Bouchard P, Spitz IM. Medical termination
of pregnancy. N Engl J Med, 2000, 342:946–956.
Collingwood TN, Urnov FD, Wolffe AP. Nuclear receptors: Coactivators,
co-repressors and chromatin remodeling in the control
of transcription. J Mol Endocrinol, 1999, 23:255–275.
Conneely OM, Mulac-Jericevic B, DeMayo F, et al.
Reproductive functions of progesterone receptors. Recent Prog
Horm Res, 2002, 57:339–355.
Coombes RC, Hall E, Gibson LJ, et al., for the Intergroup
Exemestane Study. A randomized trial of exemestane after two
to three years of tamoxifen therapy in postmenopausal women
with primary breast cancer. N Engl J Med, 2004, 350: 1081–1092.
Cullins VE. Noncontraceptive benefits and therapeutic uses of
depot medroxyprogesterone acetate. J Reprod Med, 1996,
41(suppl 5):428–433.
Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene
on risk of breast cancer in postmenopausal women:
Results from the MORE randomized trial. Multiple Outcomes
of Raloxifene Evaluation. JAMA, 1999, 281:2189–2197.
DeFriend DJ, Anderson E, Bell J, et al. Effects of 4-hydroxytamoxifen
and a novel pure antioestrogen (ICI 182780) on the
clonogenic growth of human breast cancer cells in vitro. Br J
Cancer, 1994, 70:204–211.
Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene
on bone mineral density, serum cholesterol concentrations,
and uterine endometrium in postmenopausal women.
N Engl J Med, 1997, 337:1641–1647.
Delmas PD, Ensrud KE, Adachi JD, et al. Multiple Outcomes of
Raloxifene Evaluation (MORE) Investigators. Efficacy of
raloxifene on vertebral fracture risk reduction in postmenopausal
women with osteoporosis: Four-year results from
a randomized clinical trial. J Clin Endocrinol Metab, 2002,
87:3609–3617.
DeManno D, Elger W, Garg R, et al. Asoprisnil (J867): A selective
progesterone receptor modulator for gynecological therapy.
Steroids, 2003, 68:1019–1032.
Duax WL, Griffin JF, Weeks CM, Wawrzak Z. The mechanism
of action of steroid antagonists: Insights from crystallographic
studies. J Steroid Biochem, 1988, 31:481–492.
Espeland MA, Rapp SR, Shumaker SA, et al., for the Women’s
Health Initiative Memory Study. Conjugated equine estrogens
and global cognitive function in postmenopausal women:
Women’s Health Initiative Memory Study. JAMA, 2004, 291:
2959–2968.
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral
fracture risk in postmenopausal women with osteoporosis
treated with raloxifene: Results from a 3-year randomized clinical
trial. Multiple Outcomes of Raloxifene Evaluation
(MORE) Investigators. JAMA, 1999, 282:637–645.
Fernandez E, La Vecchia C, Balducci A, et al. Oral contraceptives
and colorectal cancer risk: A meta-analysis. Br J Cancer,
2001, 84:722–727.
Fitzpatrick LA. Soy isoflavones: Hope or hype? Maturitas, 2003,
44(suppl 1):S21–S29.
Food and Drug Administration. Recommendations of DES Task
Force. FDA Drug Bull, 1985, 15:40–42.
Fotherby K. Bioavailability of orally administered sex steroids
used in oral contraception and hormone replacement therapy.
Contraception, 1996, 54:59–69.
Fruzzetti F. Hemostatic effects of smoking and oral contraceptive
use. Am J Obstet Gynecol, 1999, 180:S369–S374.
Giangrande PH, McDonnell DP. The A and B isoforms of the
human progesterone receptor: Two functionally different
transcription factors encoded by a single gene. Recent Prog
Horm Res, 1999, 54:291–313.
Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP. The
opposing transcriptional activities of the two isoforms of the
human progesterone receptor are due to differential cofactor
binding. Mol Cell Biol, 2000, 20:3102–3115.
Godsland IF. The influence of female sex steroids on glucose
metabolism and insulin action. J Intern Med Suppl, 1996,
738:1–60.
Grady D, Herrington D, Bittner V, et al., for the HERS
Research Group. Cardiovascular disease outcomes during
6.8 years of hormone therapy: Heart and Estrogen/progestin
Replacement Study follow-up (HERS II). JAMA, 2002, 288:
49–57.
Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone
therapy increases risk for venous thromboembolic disease.
Heart and Estrogen/progestin Replacement Study. Ann
Intern Med, 2000, 132:689–696.
Green PS, Simpkins JW. Neuroprotective effects of estrogens:
Potential mechanisms of action. Int J Dev Neurosci, 2000,
18:347–358.
Greenwald P, Barlow JJ, Nasca PC, Burnett WS. Vaginal cancer
after maternal treatment with synthetic estrogens. N Engl J
Med, 1971, 285:390–392.
1191
CHAPTER 40
ESTROGENS AND PROGESTINS